FRANKFURT (Reuters) - German chemicals group BASF (BASFn.DE) has agreed to sell parts of its pharmaceutical ingredients business to Swiss drug contract manufacturer Siegfried Holding (SFZN.S) for 270 million euros ($306 million), including assumed debt.
"Siegfried will reach the critical size to play a leading role in the supplier market as a recognized partner for the pharmaceutical industry," said Siegfried Chief Executive Rudolf Hanko.
02:27 Trump’s Tax Plan Is a Reckoning for Republican Deficit Hawks18
18:36 Ajit Pai announces plan to eliminate Title II net neutrality rules21
05:16 How does the ’action plan’ compare with the first 100 day reality for Donald Trump?19
09:00 Here’s how congressional Democrats plan to mark Trump’s first 100 days20